ERBB2 and breast carcinoma: The NeoSphere trial demonstrated that patients with HER2-positive breast cancer treated with pertuzumab and trastuzumab plus docetaxel in the neoadjuvant setting had higher pathologic complete response (pCR) rates than those treated with trastuzumab plus docetaxel [6].